Vinod Pullarkat
Overview
Explore the profile of Vinod Pullarkat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
4408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rahman Z, Othman T, Saliba R, Vanegas Y, Mohty R, Ledesma C, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1197-1205.
PMID: 39332807
Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subset of B-cell ALL with a poor prognosis with conventional therapies. Diagnostic challenges and lack of standardized treatment protocols contribute to...
12.
Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, et al.
Leuk Res
. 2024 Aug;
145:107565.
PMID: 39208597
Introduction: Allogeneic Hematopoietic cell transplantation (allo-HCT) remains the only curative therapy for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The impact of spliceosome mutations on allo-HCT outcome is unclear...
13.
Ngo D, Tinajero J, Song J, Ma H, Quirk E, Koller P, et al.
Leuk Lymphoma
. 2024 Aug;
65(13):2016-2024.
PMID: 39155594
Reactive pleocytosis in the CSF has been observed with blinatumomab but has not been well-described. We performed a retrospective study of 88 patients who received intrathecal chemotherapy (IT) while on...
14.
Ngo D, Tinajero J, Zhang J, Stein A, Marcucci G, Salhotra A, et al.
J Oncol Pharm Pract
. 2024 Aug;
:10781552241276547.
PMID: 39150342
Introduction: Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are...
15.
Otoukesh S, Yang D, Mokhtari S, Pourhassan H, Agrawal V, Arslan S, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1542-1551.
PMID: 39147891
The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients (n = 269) who underwent...
16.
Ross J, Lee B, Ma H, Tegtmeier B, Nanayakkara D, Dickter J, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae409.
PMID: 39135965
Background: Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers...
17.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A, et al.
Blood Adv
. 2024 Aug;
8(23):6139-6147.
PMID: 39093952
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189...
18.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Blood Adv
. 2024 Jun;
8(18):4845-4855.
PMID: 38941537
Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older...
19.
Aldoss I, Shan H, Yang D, Clark M, Al Malki M, Aribi A, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):788.e1-788.e9.
PMID: 38876428
CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy has led to unprecedented rates of complete remission (CR) in children and adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet...
20.
Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, et al.
Br J Haematol
. 2024 May;
205(2):711-715.
PMID: 38808512
No abstract available.